UK neurologists release new guidelines for JC virus testing in patients using the natalizumab biosimilar Tyruko, addressing ...
A recent study reveals global regulatory inconsistencies in biosimilars, urging convergence to enhance access and savings for patients and health care systems.
FDA's new guidance streamlines biosimilar development, reducing costs and regulatory hurdles and potentially enhancing market ...
Fifteen years have passed since the Biologics Price Competition and Innovation Act (BPCIA) transformed the biosimilar landscape. Today, we are at a crucial point: the FDA has finally removed clinical ...
Biosimilars revolutionize health care access in Latin America, offering cost savings and improved treatment availability for chronic conditions and oncology. Biosimilars possess the potential to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback